早产儿视网膜病变
医学
激光治疗
儿童失明
视网膜病变
失明
普萘洛尔
眼科
视网膜
儿科
激光治疗
验光服务
胎龄
激光器
怀孕
内科学
内分泌学
糖尿病
生物
物理
光学
遗传学
作者
Aldo Bancalari,Ricardo Schade
出处
期刊:American Journal of Perinatology
[Georg Thieme Verlag KG]
日期:2020-06-16
卷期号:39 (01): 022-030
被引量:18
标识
DOI:10.1055/s-0040-1713181
摘要
Retinopathy of prematurity (ROP) is an alteration in the development of the immature retina vascularization that frequently occurs in premature infants and is one of the leading causes of childhood blindness worldwide. In threshold stage retinopathy, laser photocoagulation is the standard treatment, particularly in those located in zone II. However, this therapy destroys parts of the retina and can lead to significant eye complications later in life. For this reason, in the last few years, antivascular endothelial growth factor agents are being used as monotherapy or as coadjuvant with laser, especially in retinopathy located in zone I. More recently, the administration of oral propranolol has been used as prevention and/or treatment of prethreshold retinopathy with encouraging results. This review provides an overview of the current evidence on newer treatment strategies for ROP. KEY POINTS: · Laser is the standard treatment in threshold retinopathy of prematurity (ROP).. · Prethreshold stages of the ROP have no treatment.. · Propranolol may prevent the progression of ROP..
科研通智能强力驱动
Strongly Powered by AbleSci AI